Plain-English translation of NCT04746066 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is an observational study—meaning researchers will collect and review medical information from patients who have inherited blood disorders (like thalassemia or sickle cell disease) and who also contracted COVID-19. No medication is being tested. Instead, the study aims to understand how COVID-19 affects people with these pre-existing blood conditions and what outcomes they experience.
Patients with chronic inherited blood disorders appear to be at higher risk when they get COVID-19. By collecting real-world information from many patients across Italy, researchers hope to learn more about how these conditions interact with the virus and how best to protect and treat affected patients.
You likely qualify if…
You likely don't qualify if…
As a participant, you would allow researchers to access and review your medical records related to your blood disorder and your COVID-19 infection. This is a registry study, meaning there are no special visits or treatments required—you simply authorize the sharing of existing medical information. The study is collecting data from up to 10,000 patients to build a better understanding of this population.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Italy
Enrollment target
~10,000 participants
Started
March 2020
Primary completion
December 2030
Last updated on clinicaltrials.gov in May 2022.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Gian Luca Forni
Ospedali Galliera - SSD Microcitemia, anemie congenite e dismetabolismo del ferro
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.